☆ 4.3 Letter

Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia

LEUKEMIA RESEARCH (2010)

Journal

LEUKEMIA RESEARCH

Volume 34, Issue 1, Pages E5-E7

Publisher

PERGAMON-ELSEVIER SCIENCE LTD

DOI: 10.1016/j.leukres.2009.08.003

Keywords

-

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Medicine, General & Internal

Chronic myeloid leukaemia

Jorge Cortes, Carolina Pavlovsky, Susanne Saussele

Summary: Tyrosine-kinase inhibitors have significantly altered the natural course of chronic myeloid leukaemia, allowing some patients to approach a near-normal life expectancy. Successful treatment requires understanding the patient's treatment goals, monitoring optimal response hallmarks, timely interventions, recognition of adverse events, and management of comorbidities.

LANCET (2021)

Add to Collection

Article Oncology

Survival with chronic myeloid leukaemia after failing milestones

Michael Lauseker, Ruediger Hehlmann, Andreas Hochhaus, Susanne Saussele

Summary: The therapy after failing response milestones in CML is controversial, and there is a lack of information on the long-term survival of these patients. A study on patients from CML-study IV showed that the survival rate of patients who failed the failure milestones was approximately 10% lower than those who reached the milestones, suggesting a need for revising these milestones.

LEUKEMIA (2023)

Add to Collection

Article Multidisciplinary Sciences

Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia

Yotaro Ochi, Kenichi Yoshida, Ying-Jung Huang, Ming-Chung Kuo, Yasuhito Nannya, Ko Sasaki, Kinuko Mitani, Noriko Hosoya, Nobuhiro Hiramoto, Takayuki Ishikawa, Susan Branford, Naranie Shanmuganathan, Kazuma Ohyashiki, Naoto Takahashi, Tomoiku Takaku, Shun Tsuchiya, Nobuhiro Kanemura, Nobuhiko Nakamura, Yasunori Ueda, Satoshi Yoshihara, Rabindranath Bera, Yusuke Shiozawa, Lanying Zhao, June Takeda, Yosaku Watatani, Rurika Okuda, Hideki Makishima, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Masashi Sanada, Akifumi Takaori-Kondo, Satoru Miyano, Seishi Ogawa, Lee-Yung Shih

Summary: In chronic myeloid leukaemia (CML), the drivers of blast crisis and resistance to tyrosine kinase inhibitors are not fully characterised. Analysis of a cohort of CML samples using genomic technologies reveals that at least one driver alteration is associated with progression and worse prognosis. Genetic abnormalities can help predict clinical outcomes and guide clinical decisions in CML.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients

Sarah Allegra, Emma Dondi, Francesco Chiara, Silvia De Francia

Summary: This study examined the influence of age and sex on the levels of tyrosine kinase inhibitors in plasma and cerebrospinal fluid of patients with chronic myeloid leukaemia. Results showed an inverse correlation between age and imatinib plasma concentration, and lower dasatinib concentrations in plasma compared to cerebrospinal fluid, especially in paediatric patients. Therapeutic drug monitoring, along with tyrosine kinase inhibitors, is supported for the treatment of chronic myeloid leukaemia. Refinement of the classification of tyrosine kinase inhibitor therapeutic drug monitoring should consider factors like sex and age.

BIOMEDICINES (2023)

Add to Collection

Article Oncology

Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia

Michele Baccarani, Francesca Bonifazi, Simona Soverini, Fausto Castagnetti, Gabriele Gugliotta, Wael Saber, Noel Estrada-Merly, Gianantonio Rosti, Robert Peter Gale

Summary: This commentary discusses important questions regarding the treatment of chronic myeloid leukaemia (CML) and compares the benefits and risks of tyrosine kinase-inhibitor (TKI) therapy and transplantation. The authors suggest that a small proportion of patients with CML can achieve sustained therapy-free remission with TKI therapy, while others may need lifelong treatment. Transplants offer higher rates of leukaemia-free survival, but are associated with adverse events and complications. The authors propose that transplantation should be considered more often as a treatment option for CML patients unlikely to achieve therapy-free remission with TKI therapy.

LEUKEMIA (2022)

Add to Collection

Article Hematology

Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1

Huimin Feng, Yue Fu, Zelong Cui, Minran Zhou, Lu Zhang, Zhenxing Gao, Sai Ma, Chunyan Chen

Summary: This study shows that PHF8 is significantly increased in CML patients and inhibits cell differentiation while promoting cell proliferation. Targeting PHF8, which directly regulates BCR::ABL1 expression, may be a useful therapeutic approach for CML.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Combination of curaxin and tyrosine kinase inhibitors display enhanced killing of primitive Chronic Myeloid Leukaemia cells

Stella Pearson, Anthony D. Whetton, Andrew Pierce

Summary: Despite advances in precision medicine targeted therapies for cancer, the development of curative treatments remains challenging due to drug resistance in cancer stem cells. Chronic myeloid leukemia is a model for studying cancer stem cells and although targeted therapies have been developed, drug resistance remains a problem. New treatment strategies are needed to target other components within leukemia stem cells, either alone or in combination with existing therapies.

PLOS ONE (2022)

Add to Collection

Article Oncology

Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia

Richard E. Clark, Ammar A. Basabrain, Gemma M. Austin, Alison K. Holcroft, Sandra Loaiza, Jane F. Apperley, Christopher Law, Laura Scott, Alexandra D. Parry, Laura Bonnett, Claire M. Lucas

Summary: The high levels of diagnostic CIP2A are associated with disease progression and treatment failure in chronic myeloid leukemia patients, making it a potentially useful diagnostic tool for treatment planning.

CANCERS (2021)

Add to Collection

Article Hematology

BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase

Dennis Dong Hwan Kim, Taehyung Simon Kim, Eshetu G. Atenafu, Igor Novitzky Basso, Donna Forrest, Isabelle Bence-Bruckler, Lynn Savoie, Lambert Busque, Mary-Margaret Keating, Robert Delage, Anargyros Xenocostas, Elena Liew, Kristjan Paulson, Tracy Stockley, Pierre Laneuville, Jeffrey H. Lipton, Suzanne Kamel-Reid, Brian Leber

Summary: The study found that monthly assessment of doubling time can help identify the risk of molecular recurrence in patients with chronic myeloid leukemia after discontinuation of imatinib, thereby distinguishing between high-risk and low-risk patients.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Review Hematology

Asciminib for chronic myeloid leukaemia: Next questions

Naranie Shanmuganathan, Timothy P. Hughes

Summary: The recent approval of asciminib as a treatment option for CML patients provides clinicians with more choices for therapy. Asciminib is a highly potent BCR-ABL1 inhibitor with limited off-target effects, but its position among other available TKIs is still unclear. There are many unanswered questions about the optimal use of asciminib.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

NOX2 and NOX4 control mitochondrial function in chronic myeloid leukaemia

Marta Romo-Gonzalez, Carla Ijurko, Maria Teresa Alonso, Marta Gomez de Cedron, Ana Ramirez de Molina, Maria Eugenia Soriano, Angel Hernandez-Hernandez

Summary: Cancer cells exhibit an altered metabolism and increased production of ROS, both of which play important roles in cancer and have potential therapeutic implications. Recent studies have highlighted the importance of NOX enzymes in connecting ROS production and metabolic control. In this study, the relevance of NOX2 and NOX4 in regulating metabolism and mitochondrial function in CML cells was explored. The results support the role of NOX2 in controlling metabolism-related signaling pathways downstream of BCR-ABL, and highlight the role of NOX4 in altering mitochondrial function.

FREE RADICAL BIOLOGY AND MEDICINE (2023)

Add to Collection

Article Hematology

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018

Carolien C. H. M. Maas, David van Klaveren, Genevieve I. C. G. Ector, Eduardus F. M. Posthuma, Otto Visser, Peter E. Westerweel, Jeroen J. W. M. Janssen, Nicole M. A. Blijlevens, Avinash G. Dinmohamed

Summary: A study in the Netherlands revealed that patients with CML who survived several years after diagnosis had life expectancies nearly equivalent to the general population, regardless of age. This was attributed to the introduction and widespread use of TKIs, offering hope to CML patients for a near-normal life expectancy in the modern TKI era.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Plant Sciences

Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia

Rubin Cheng, Yilan Huang, Yun Fang, Qirui Wang, Meixiu Yan, Yuqing Ge

Summary: The study demonstrated that CPT could significantly enhance the antileukemia efficacy of TKIs through triggering cleavages of caspase proteins and inhibiting activities of STAT3 and eIF4E pathways. The combination treatment of CPT and imatinib significantly inhibited tumor growth, achieved a suppression of 60.2%, and increased apoptotic rates while decreasing phosphorylation levels of STAT3 and eIF4E.

PHARMACEUTICAL BIOLOGY (2021)

Add to Collection

Editorial Material Oncology

Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient

Eda Nuhoglu Kantarci, Ece Tolgay, Ahmet Emre Eskazan

Summary: This editorial discusses the search for the best patient-based treatment option as well as evaluates a recent study by Tiribelli et al., published in Cancer.

CANCER (2023)

Add to Collection

Article Oncology

Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan

Hsi-Che Liu, Ming-Chung Kuo, Kang-Hsi Wu, Tsai-Yun Chen, Jiann-Shiuh Chen, Ming-Chung Wang, Tung-Liang Lin, YoungSen Yang, Ming-Chun Ma, Po-Nan Wang, Jiunn-Ming Sheen, Shih-Chung Wang, Shih-Hsiang Chen, Tang-Her Jaing, Chao-Neng Cheng, Ting-Chi Yeh, Tung-Huei Lin, Lee-Yung Shih

Summary: In this multicenter study, the molecular responses and outcomes of pediatric and adult patients with chronic phase chronic myeloid leukemia (CML) treated with front-line imatinib (IM) were compared. The pediatric cohort exhibited slower molecular responses but similar 10-year progression-free survival and overall survival rates compared to the adult cohort.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Article Endocrinology & Metabolism

Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an ITAS post hoc analysis

Raffaella Buzzetti, Riccardo C. Bonadonna, Andrea Giaccari, Gianluca Perseghin, Domenico Cucinotta, Carmine Fanelli, Angelo Avogaro, Gianluca Aimaretti, Monica Larosa, Ilaria Pacchetti, Geremia B. Bolli

DIABETES OBESITY & METABOLISM (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association Between Platelet Reactivity and Long-Term Bleeding Complications After Percutaneous Coronary Intervention According to Diabetes Status

Ilaria Cavallari, Giuseppe Patti, Ernesto Maddaloni, Francesco Veneziano, Fabio Mangiacapra, Elisabetta Ricottini, Raffaella Buzzetti, Gian Paolo Ussia, Francesco Grigioni

Summary: This study investigated the role of low platelet reactivity (LPR) in the bleeding risk stratification of patients who underwent percutaneous coronary intervention (PCI) according to their diabetes mellitus (DM) status. The results showed that LPR provided significant incremental value for predicting bleeding, regardless of DM status. The coexistence of DM and LPR identified the subgroup with the highest bleeding risk.

AMERICAN JOURNAL OF CARDIOLOGY (2022)

Add to Collection

Review Hematology

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success

Elena Inzoli, Andrea Aroldi, Rocco Piazza, Carlo Gambacorti-Passerini

Summary: Discontinuation of TKI has been proven to be safe and feasible in CML patients with deep and durable molecular responses, introducing a new treatment goal. However, a precise stratification of patients based on their risk of relapse using clinical and biological factors is still lacking. This article aims to review leading studies in the field to define eligibility criteria for discontinuation and predictors of success.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Editorial Material Endocrinology & Metabolism

Third dose of COVID-19 vaccine in diabetes: Relevance of good metabolic control to improve its efficacy

Silvia Pieralice, Luca D'Onofrio, Paolo Pozzilli, Raffaella Buzzetti

DIABETES-METABOLISM RESEARCH AND REVIEWS (2022)

Add to Collection

Review Endocrinology & Metabolism

C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective

Ernesto Maddaloni, Geremia B. Bolli, Brian M. Frier, Randie R. Little, Richard D. Leslie, Paolo Pozzilli, Raffaela Buzzetti

Summary: C-peptide measurement is valuable in autoimmune diabetes but limited in type 2 diabetes due to confounding factors like insulin resistance. Standardization issues exist that may affect comparability between different laboratories.

DIABETES OBESITY & METABOLISM (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1? generation basal insulins

Raffaella Buzzetti, Gian Paolo Fadini, Antonio Nicolucci, Monica Larosa, Maria Chiara Rossi, Domenico Cucinotta

Summary: The study found that switching to second generation basal insulin from first generation basal insulin in patients with type 2 diabetes can improve glycemic control, reduce hypoglycemia rates, and avoid weight gain. However, clinical inertia in Italy, represented by late treatment intensification and suboptimal titration of basal insulin doses, remains a major issue.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2022)

Add to Collection

Letter Hematology

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas

Giovanni Rindone, Andrea Aroldi, Elisa Bossi, Luisa Verga, Giovanni Zambrotta, Sara Tarantino, Rocco Piazza, Lara Mussolin, Roberto Chiarle, Carlo Gambacorti-Passerini

BLOOD ADVANCES (2023)

Add to Collection

Article Medicine, General & Internal

Adult-onset autoimmune diabetes

Raffaella Buzzetti, Ernesto Maddaloni, Jason Gaglia, R. David Leslie, F. Susan Wong, Bernhard O. Boehm

Summary: Adult-onset autoimmune diabetes is often misdiagnosed as type 2 diabetes and has a slow progression. Proper care aims to prevent complications and improve quality of life. Choosing the right therapy for this disease is challenging due to its heterogeneity.

NATURE REVIEWS DISEASE PRIMERS (2022)

Add to Collection

Review Endocrinology & Metabolism

Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials

Ernesto Maddaloni, Ilaria Cavallari, Ylenia La Porta, Alessandro Appetecchia, Luca D'Onofrio, Francesco Grigioni, Raffaella Buzzetti, Rury R. Holman

Summary: The study found that SGLT2 inhibitors can reduce the risk of renal impairment and heart failure. Furthermore, the efficacy of SGLT2 inhibitors in terms of kidney protection is related to the baseline estimated glomerular filtration rate, with the best results seen in patients who initiate treatment early and have a higher eGFR. The greatest reduction in heart failure risk is observed in patients with a lower eGFR.

DIABETES OBESITY & METABOLISM (2023)

Add to Collection

Article Hematology

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia

Elena Inzoli, Elena Crisa, Novella Pugliese, Ivan Civettini, Giuseppe Lanzarone, Andrea Castelli, Vincenzo Martinelli, Laura Montelisciani, Laura Antolini, Carlo Gambacorti-Passerini, Elena Maria Elli

Summary: This study retrospectively collected data on 96 MF patients treated with B-ESA and found that 80% of patients obtained anemia response. The median time to anemia response was 2.5 months. The 24-month survival was significantly affected by the response to B-ESA.

EUROPEAN JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Review Endocrinology & Metabolism

Diabetes, COVID-19, and questions unsolved

Felecia D'Souza, Raffaella Buzzetti, Paolo Pozzilli

Summary: Recent evidence suggests that diabetes is associated with increased risk and adverse outcomes from COVID-19 infection. The mechanisms include dysregulation of specific enzymes and impaired immune responses, exacerbated by hyperglycemia. Limited studies on COVID-19 vaccination in people with diabetes show that vaccination is protective against adverse outcomes. People with diabetes should be prioritized in vaccination efforts and blood sugar optimization is essential in reducing their COVID-19-associated risk.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2023)

Add to Collection

Article Oncology

Single-center study on SARS-CoV-2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization

Ivan Civettini, Laura Antolini, Filippo Brioschi, Giovanni Paolo Maria Zambrotta, Veronica Guglielmana, Carlo Gambacorti-Passerini

Summary: This study aimed to evaluate the impact of COVID-19 on Chronic Myeloid Leukemia (CML) patients by assessing mortality-hospitalization rates and identifying protective factors. Vaccination and treatment with Bosutinib were found to decrease the risk of hospitalization caused by COVID-19 infection.

CANCER MEDICINE (2023)

Add to Collection

Article Endocrinology & Metabolism

Validation in type 2 diabetes of a metabolomic signature of all-cause mortality

Massimiliano Copetti, Marco Giorgio Baroni, Raffaella Buzzetti, Maria Gisella Cavallo, Efiso Cossu, Paola D'Angelo, Salvatore De Cosmo, Frida Leonetti, Susanna Morano, Lelio Morviducci, Nicola Napoli, Sabrina Prudente, Giuseppe Pugliese, Antonio Fernando Savino, Vincenzo Trischitta

Summary: This study aimed to validate the association of a 14-metabolite score with all-cause mortality in type 2 diabetes and explore whether it could improve existing mortality prediction models. The results showed a significant association between the 14-metabolite score and mortality in type 2 diabetes, although the effect size was lower compared to the general population. However, a simplified version of the score without two specific metabolites improved patient analysis and classification of mortality risk.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Lack of Association between Serum Chitotriosidase Activity and Arterial Stiffness in Type 2 Diabetes without Cardiovascular Complications

Luca D'Onofrio, Rocco Amendolara, Carmen Mignogna, Gaetano Leto, Lida Tartaglione, Sandro Mazzaferro, Ernesto Maddaloni, Raffaella Buzzetti

Summary: This study evaluated CHIT activity as an early biomarker of arterial stiffness in T2D patients without overt vascular complications. The results showed no association between CHIT activity and arterial stiffness, but the high-PWV group had other CVD risk factors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Oncology

Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study

Gianantonio Rosti, Tim H. Bruemmendorf, Bjoern T. Gjertsen, Pilar Giraldo-Castellano, Fausto Castagnetti, Carlo Gambacorti-Passerini, Thomas Ernst, Huadong Zhao, Luke Kuttschreuter, Simon Purcell, Francis J. Giles, Andreas Hochhaus

Summary: The phase 4 BYOND trial evaluated the efficacy and safety of bosutinib in pretreated CML patients. The study found that a significant proportion of patients achieved or maintained cytogenetic and molecular responses across different age groups and comorbidity scores. However, older patients (>=75 years) and those with higher comorbidity burden (mCCI >= 4) may require closer monitoring due to increased risk of adverse events.

LEUKEMIA (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.